These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

427 related items for PubMed ID: 14744261

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
    Eisold M, Asim M, Eskelinen H, Linke T, Baniahmad A.
    J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455
    [Abstract] [Full Text] [Related]

  • 3. A novel mutation F826L in the human androgen receptor in partial androgen insensitivity syndrome; increased NH2-/COOH-terminal domain interaction and TIF2 co-activation.
    Wong HY, Hoogerbrugge JW, Pang KL, van Leeuwen M, van Royen ME, Molier M, Berrevoets CA, Dooijes D, Dubbink HJ, van de Wijngaart DJ, Wolffenbuttel KP, Trapman J, Kleijer WJ, Drop SL, Grootegoed JA, Brinkmann AO.
    Mol Cell Endocrinol; 2008 Sep 24; 292(1-2):69-78. PubMed ID: 18656523
    [Abstract] [Full Text] [Related]

  • 4. The androgen receptor T877A mutant recruits LXXLL and FXXLF peptides differently than wild-type androgen receptor in a time-resolved fluorescence resonance energy transfer assay.
    Ozers MS, Marks BD, Gowda K, Kupcho KR, Ervin KM, De Rosier T, Qadir N, Eliason HC, Riddle SM, Shekhani MS.
    Biochemistry; 2007 Jan 23; 46(3):683-95. PubMed ID: 17223690
    [Abstract] [Full Text] [Related]

  • 5. Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors.
    Hodgson MC, Astapova I, Hollenberg AN, Balk SP.
    Cancer Res; 2007 Sep 01; 67(17):8388-95. PubMed ID: 17804755
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Partial agonist/antagonist properties of androstenedione and 4-androsten-3beta,17beta-diol.
    Chen F, Knecht K, Leu C, Rutledge SJ, Scafonas A, Gambone C, Vogel R, Zhang H, Kasparcova V, Bai C, Harada S, Schmidt A, Reszka A, Freedman L.
    J Steroid Biochem Mol Biol; 2004 Aug 01; 91(4-5):247-57. PubMed ID: 15336702
    [Abstract] [Full Text] [Related]

  • 8. Antiandrogens prevent stable DNA-binding of the androgen receptor.
    Farla P, Hersmus R, Trapman J, Houtsmuller AB.
    J Cell Sci; 2005 Sep 15; 118(Pt 18):4187-98. PubMed ID: 16141232
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Antiandrogenic activity of norgestimate in a human androgen-dependent stable-transfected cell line.
    Paris F, Rabeolina F, Balaguer P, Bacquet A, Sultan C.
    Gynecol Endocrinol; 2007 Apr 15; 23(4):193-7. PubMed ID: 17505938
    [Abstract] [Full Text] [Related]

  • 11. The corepressors silencing mediator of retinoid and thyroid hormone receptor and nuclear receptor corepressor are involved in agonist- and antagonist-regulated transcription by androgen receptor.
    Yoon HG, Wong J.
    Mol Endocrinol; 2006 May 15; 20(5):1048-60. PubMed ID: 16373395
    [Abstract] [Full Text] [Related]

  • 12. Antiandrogen effects of mifepristone on coactivator and corepressor interactions with the androgen receptor.
    Song LN, Coghlan M, Gelmann EP.
    Mol Endocrinol; 2004 Jan 15; 18(1):70-85. PubMed ID: 14593076
    [Abstract] [Full Text] [Related]

  • 13. Coregulator recruitment and histone modifications in transcriptional regulation by the androgen receptor.
    Kang Z, Jänne OA, Palvimo JJ.
    Mol Endocrinol; 2004 Nov 15; 18(11):2633-48. PubMed ID: 15308689
    [Abstract] [Full Text] [Related]

  • 14. Agonist-antagonist induced coactivator and corepressor interplay on the human androgen receptor.
    Dotzlaw H, Papaioannou M, Moehren U, Claessens F, Baniahmad A.
    Mol Cell Endocrinol; 2003 Dec 31; 213(1):79-85. PubMed ID: 15062576
    [Abstract] [Full Text] [Related]

  • 15. Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer.
    Agoulnik IU, Vaid A, Nakka M, Alvarado M, Bingman WE, Erdem H, Frolov A, Smith CL, Ayala GE, Ittmann MM, Weigel NL.
    Cancer Res; 2006 Nov 01; 66(21):10594-602. PubMed ID: 17079484
    [Abstract] [Full Text] [Related]

  • 16. Prostate cancer cells increase androgen sensitivity by increase in nuclear androgen receptor and androgen receptor coactivators; a possible mechanism of hormone-resistance of prostate cancer cells.
    Fujimoto N, Miyamoto H, Mizokami A, Harada S, Nomura M, Ueta Y, Sasaguri T, Matsumoto T.
    Cancer Invest; 2007 Feb 01; 25(1):32-7. PubMed ID: 17364555
    [Abstract] [Full Text] [Related]

  • 17. Stromal-epithelial cell interactions and androgen receptor-coregulator recruitment is altered in the tissue microenvironment of prostate cancer.
    Cano P, Godoy A, Escamilla R, Dhir R, Onate SA.
    Cancer Res; 2007 Jan 15; 67(2):511-9. PubMed ID: 17234758
    [Abstract] [Full Text] [Related]

  • 18. 11beta-alkyl-Delta9-19-nortestosterone derivatives: high-affinity ligands and potent partial agonists of the androgen receptor.
    Muddana SS, Price AM, MacBride MM, Peterson BR.
    J Med Chem; 2004 Oct 07; 47(21):4985-8. PubMed ID: 15456242
    [Abstract] [Full Text] [Related]

  • 19. Study of the impact of the T877A mutation on ligand-induced helix-12 positioning of the androgen receptor resulted in design and synthesis of novel antiandrogens.
    Zhou J, Liu B, Geng G, Wu JH.
    Proteins; 2010 Feb 15; 78(3):623-37. PubMed ID: 19787772
    [Abstract] [Full Text] [Related]

  • 20. Effects of steroidal and non-steroidal antiandrogens on wild-type and mutant androgen receptors.
    Urushibara M, Ishioka J, Hyochi N, Kihara K, Hara S, Singh P, Isaacs JT, Kageyama Y.
    Prostate; 2007 Jun 01; 67(8):799-807. PubMed ID: 17373727
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.